Digital Healthcare Company Healios Gets £7M to Offer Tailored Therapy to Children and Young People Across the UK
Raised £7 million
Recently, the UK company raised £7 million funding in a Series A round led by InHealth Ventures with participation from existing investors AlbionVC.
InHealth Ventures and InHealth Group Chair, Richard Bradford, will be joining the Healios board, alongside Cat McDonald of AlbionVC.
How will the funding be used?
The funding will be used to invest in new assessment and treatment programmes, enabling it to make even more services available to the NHS and health organisations.
The company will also expand its AI, machine learning, and data science expertise, adding to a team whose headcount has already grown by 116% since early 2020.
In addition, Healios will be accelerating plans to expand internationally later this year.
Pioneering family intervention and behavioural change
Founded in 2013, Healios virtual care platform delivers tailored digital interventions including specialist clinical assessments, therapy sessions, and bespoke support programmes through its employed network of sector-leading clinicians, integrated tools, self-management apps, and a telemedicine platform.
So far, more than 70,000 specialised clinical sessions have been delivered through Healios, claims the company.
These digital interventions reduce waiting times for assessment and treatment and infrastructure costs for NHS Trusts.
Healios takes a family-centric approach to assessment, therapy, and treatment plans, with research showing that involving loved ones in the care process significantly improves clinical outcomes for patients.
This approach has seen Healios develop and launch the world’s first online, family-focused therapy programme for young people with psychosis and schizophrenia.
Endorsements from NICE
The Healios virtual care management platform has received endorsements from the National Institute for Health and Care Excellence (NICE) for its Cognitive Behavioural Therapy in Children and Young People service and their Family Intervention for Psychosis and Schizophrenia service.
Healios’ Autism Assessment Service was also included in NHS England’s National Autism Best Practice Guide.
Rich Andrews, Founder, and CEO of Healios said: “The UK is facing a mental health crisis. Demand far outstrips supply and technology has a vital role to play in closing that gap. We’re immensely proud of the lives we’ve already changed through Healios. This funding will help us reach more families in need and enable us to develop further sector-leading interventions and therapies. By bringing together clinical experts and giving them the tools to reach their patients regardless of where they are, we are closing the access gap which has plagued mental health provision for far too long.
“We’re delighted to bring such esteemed investors onto the team as we deepen our clinical provision and expand our global reach. Both InHealth Ventures and existing investors AlbionVC bring with them highly specialised knowledge when it comes to navigating health systems and scaling innovative healthcare technologies.”
Dr. Ben Evans, Managing Director of InHealth Ventures, said: “Healios is a standard-bearer for healthcare innovation. They bring together clinical excellence with digital expertise, working in partnership with the NHS to address a critical, but complex area of care delivery. Helios work to date speaks for itself; their holistic approach to diagnosis and treatment has had a substantive impact on clinical outcomes and patient experience. We’re thrilled to have led this round and are excited to partner with the Healios team as they continue their pioneering and hugely important work.”
Cat McDonald, Investor at AlbionVC, said: “Covid has engendered a pace of innovation previously unseen in healthcare. In particular, we have seen that remote care not only works but often works much better than traditional alternatives. The option to receive care remotely, at home, and in a family-centric setting is the strong preference of most kids suffering from poor mental health, which is why we are delighted to continue supporting the incredible Healios team as they continue on their mission of bringing accessible care to the next generation”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more